logo
3 million Koreans sign refusal of life-prolonging treatment

3 million Koreans sign refusal of life-prolonging treatment

Korea Herald10-08-2025
Increasing number of people are saying no to end-of-life care, choosing to 'die with dignity'
A little over 3 million people in South Korea have signed forms to refuse life-sustaining treatments in case of untreatable diseases, a choice referred to in ethics as a "dignified death."
According to the state-run National Agency for Management of Life-sustaining Treatment, the number of people who signed the advance statement had surpassed the 3 million mark as of Saturday, accounting for 6.8 percent of the country's adult population.
The system of legally allowing the discontinuation of treatment for incurable diseases was implemented in February 2018, with the passage of the Act on Hospice and Palliative Care and Decisions on Life-sustaining Treatment for Patients at the End of Life. The number of those who had signed advance statements reached 86,691 by the end of 2018, but it quickly rose to 1.16 million by 2021, then nearly doubled to 2.15 million by 2023, and rose by almost another million over the next two years.
Women account for two-thirds of those who have decided to refuse life-sustaining treatment, and 21 percent of all people aged 65 and older have signed the statement.
A total of 443,874 people have had their life-sustaining treatment discontinued since the system was introduced.
Talks on expanding refusal of life-sustaining treatment
The current system has strict criteria for pulling the plug on patients suffering from incurable diseases. Article 2 of the related act says it is permitted only for patients in the "end-of-life process," which means a state of imminent death with no possibility of revitalization or recovery.
Terminal patients are defined in the law as those who are expected to die within a few months, according to a diagnosis from a doctor in charge and one medical specialist in the relevant field.
The issue touched off controversy in a 2023 case of a patient in his 60s with terminal cancer, who had remained unconscious for weeks in the hospital. Despite having signed a refusal of life-prolonging treatment and his wife asking the doctors to pull the plug after three weeks, doctors' hands were tied due to the specific conditions in the law.
He remained unconscious for another week before passing away.
Lawmakers are discussing a broader application of the related law, such as a proposal by Rep. Nam In-soon of the Democratic Party of Korea and 15 other liberal lawmakers in 2024. The revision would allow an end of treatment for patients in the "final stages" of a disease, which include the terminal stage but also the period leading up to likely death.
"Extending the (stopping of life-sustaining treatment) to the final stage will give patients enough time to think it over and reach a decision, strengthening their right to decide and preserving their dignity as human beings," Nam said. The bill is currently pending deliberation at the National Assembly.
Jung Eun-kyeong, the recently appointed minister of health and welfare, also said she recognizes the necessity of expanding eligibility in the current system.
A report in May by local broadcaster KBS showed that in a government survey of 27 heads of medical societies in the country, 82 percent agreed that the existing law should be expanded to include patients in the final stages of terminal disease.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

3 million Koreans sign refusal of life-prolonging treatment
3 million Koreans sign refusal of life-prolonging treatment

Korea Herald

time10-08-2025

  • Korea Herald

3 million Koreans sign refusal of life-prolonging treatment

Increasing number of people are saying no to end-of-life care, choosing to 'die with dignity' A little over 3 million people in South Korea have signed forms to refuse life-sustaining treatments in case of untreatable diseases, a choice referred to in ethics as a "dignified death." According to the state-run National Agency for Management of Life-sustaining Treatment, the number of people who signed the advance statement had surpassed the 3 million mark as of Saturday, accounting for 6.8 percent of the country's adult population. The system of legally allowing the discontinuation of treatment for incurable diseases was implemented in February 2018, with the passage of the Act on Hospice and Palliative Care and Decisions on Life-sustaining Treatment for Patients at the End of Life. The number of those who had signed advance statements reached 86,691 by the end of 2018, but it quickly rose to 1.16 million by 2021, then nearly doubled to 2.15 million by 2023, and rose by almost another million over the next two years. Women account for two-thirds of those who have decided to refuse life-sustaining treatment, and 21 percent of all people aged 65 and older have signed the statement. A total of 443,874 people have had their life-sustaining treatment discontinued since the system was introduced. Talks on expanding refusal of life-sustaining treatment The current system has strict criteria for pulling the plug on patients suffering from incurable diseases. Article 2 of the related act says it is permitted only for patients in the "end-of-life process," which means a state of imminent death with no possibility of revitalization or recovery. Terminal patients are defined in the law as those who are expected to die within a few months, according to a diagnosis from a doctor in charge and one medical specialist in the relevant field. The issue touched off controversy in a 2023 case of a patient in his 60s with terminal cancer, who had remained unconscious for weeks in the hospital. Despite having signed a refusal of life-prolonging treatment and his wife asking the doctors to pull the plug after three weeks, doctors' hands were tied due to the specific conditions in the law. He remained unconscious for another week before passing away. Lawmakers are discussing a broader application of the related law, such as a proposal by Rep. Nam In-soon of the Democratic Party of Korea and 15 other liberal lawmakers in 2024. The revision would allow an end of treatment for patients in the "final stages" of a disease, which include the terminal stage but also the period leading up to likely death. "Extending the (stopping of life-sustaining treatment) to the final stage will give patients enough time to think it over and reach a decision, strengthening their right to decide and preserving their dignity as human beings," Nam said. The bill is currently pending deliberation at the National Assembly. Jung Eun-kyeong, the recently appointed minister of health and welfare, also said she recognizes the necessity of expanding eligibility in the current system. A report in May by local broadcaster KBS showed that in a government survey of 27 heads of medical societies in the country, 82 percent agreed that the existing law should be expanded to include patients in the final stages of terminal disease.

Alteogen Receives Positive CHMP Opinion for Aflibercept Biosimilar, 'EYLUXVI® (ALT-L9)'
Alteogen Receives Positive CHMP Opinion for Aflibercept Biosimilar, 'EYLUXVI® (ALT-L9)'

Korea Herald

time28-07-2025

  • Korea Herald

Alteogen Receives Positive CHMP Opinion for Aflibercept Biosimilar, 'EYLUXVI® (ALT-L9)'

DAEJEON, South Korea, July 28, 2025 /PRNewswire/ -- Alteogen Inc. (KOSDAQ:196170) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for EYLUXVI ® (code name: ALT-L9), a biosimilar referencing Eylea ® (aflibercept), co-developed with its subsidiary Alteogen Biologics Inc. EYLUXVI ® has been recommended for approval in adult patients for the treatment of neovascular (wet) age-related macular degeneration (AMD), visual impairment due to macular oedema secondary to retinal vein occlusion (branch [RVO] or central [RVO]), visual impairment due to diabetic macular oedema (DME), and visual impairment due to myopic choroidal neovascularisation (myopic CNV). "We are pleased to receive a positive CHMP recommendation for EYLUXVI ®. This marks a significant milestone for Alteogen," said Soon-Jae Park, PhD, Chief Executive Officer of Alteogen. "We will provide a new, accessible treatment option for patients suffering from devastating ocular diseases such as wet age-related macular degeneration," he added. The positive CHMP opinion was based on the totality of evidence comprising a comprehensive analytical, non-clinical and clinical data package. A randomized, double-masked, parallel group, multicenter Phase 3 study, conducted by Alteogen Biologics, demonstrated equivalent efficacy and comparable safety, immunogenicity, and pharmacokinetics (PK) profiles between EYLUXVI ® and reference aflibercept in patients with wet AMD. Meanwhile, Alteogen licensed the development and commercialization rights for its anti-cancer drug Herceptin ® biosimilar, ALT-L2, for the Chinese market to Qilu Pharmaceutical in 2017. Qilu Pharmaceutical completed its development, obtained approval from Chinese regulatory authorities last year, and is currently marketing the product in China. If approved, EYLUXVI ® will be Alteogen's second commercialized biosimilar product. About the ALT-L9 Phase 3 study The study is a randomized, double-masked, parallel group phase 3 study conducted at 79 centers in 12 countries from June 2022 to February 2024, including follow-up through 52 weeks. 431 participants with wet AMD were randomized 1:1 to receive either ALT-L9 (n = 216) or Eylea® (n = 215). The primary efficacy endpoint of the study was the change from baseline in best corrected visual acuity (BCVA). About Alteogen Alteogen Inc. is a South Korea-based biopharmaceutical company that focuses on the development and commercialization of novel biologics such as Antibody-Drug Conjugates (ADCs), biobetters, and biosimilars. Alteogen's portfolio includes clinical-stage long-acting therapeutic proteins and next-generation ADCs, developed by its proprietary NexP™-fusion and NexMab™ platform technology, respectively. It also developed a proprietary recombinant human hyaluronidase enzyme utilizing Hybrozyme™ technology, which enables the large volume subcutaneous administration of drugs that are typically administered as an IV infusion. The company was founded in 2008 and listed in KOSDAQ ( For more information, please visit: Contacts:

Miracell launches Korea's first generative AI voice system for hospitals
Miracell launches Korea's first generative AI voice system for hospitals

Korea Herald

time25-07-2025

  • Korea Herald

Miracell launches Korea's first generative AI voice system for hospitals

Korean stem cell research company Miracell has introduced the nation's first generative AI-powered voice consultation system designed for medical institutions. Co-developed with Europe-based Vee, a Warsaw-listed AI company, the solution marks a major shift in healthcare automation. The company said Monday it has secured exclusive distribution rights for Vee's AI solution across Asia and is working closely with Vee Korea to customize the system for local hospitals. Unlike traditional rule-based ARS systems, the new AI tool uses natural language processing to deliver 24-hour conversational support, handling appointment scheduling, billing inquiries, patient reminders and general questions. The system is particularly effective during nights and weekends, when staffing is limited. It integrates with hospital customer relationship management systems and supports both inbound and outbound calls. Hospitals can trial the solution free for one month, lowering the adoption barrier. 'Generative AI can dramatically improve service quality in medical care,' said Shin Hyun-soon, CEO of Miracell. 'This isn't just an upgrade — it's a survival strategy for the health care sector.' Vee provides the underlying large language model engine, customized for Korean language and clinical context. A future version will link with Miracell's Celldoc platform, integrating patient consultations, appointments, and treatment records into a single interface. By combining its stem cell expertise with cutting-edge AI, Miracell aims to set a new standard in the health care industry. 'We're starting with clinics already using Smart-MCell,' a Miracell spokesperson said. 'But this is just the beginning. With AI, we hope to bring patients and caregivers even closer, and open the door to a more responsive, intelligent health care experience.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store